Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1096

—

39a3ebba-efd1-5e4c-b4f3-738d0ac44389

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_GAMMA_RESPONSE+0.421
  • INTERFERON_ALPHA_RESPONSE+0.406
  • ALLOGRAFT_REJECTION+0.400
  • IL6_JAK_STAT3_SIGNALING+0.259
  • INFLAMMATORY_RESPONSE+0.254
  • APICAL_SURFACE+0.212
  • WNT_BETA_CATENIN_SIGNALING+0.203
  • KRAS_SIGNALING_UP+0.157
  • ANGIOGENESIS+0.154
  • COMPLEMENT+0.102

Top 10 suppressed

  • PROTEIN_SECRETION-0.469
  • CHOLESTEROL_HOMEOSTASIS-0.424
  • ANDROGEN_RESPONSE-0.406
  • TGF_BETA_SIGNALING-0.369
  • MTORC1_SIGNALING-0.355
  • MYC_TARGETS_V1-0.353
  • HEDGEHOG_SIGNALING-0.348
  • UNFOLDED_PROTEIN_RESPONSE-0.345
  • ESTROGEN_RESPONSE_EARLY-0.333
  • HEME_METABOLISM-0.273

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG585
mng-umap@100
——0.838
2SRR8518351
breast-umap@18
—D0.835
3TCGA-OR-A5L6-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.807
4TCGA-49-AAR3-01A-11R-A41B-07
lung-landscapes@6
—cohortA10.805
5TCGA-90-A59Q-01A-11R-A26W-07
lung-landscapes@6
—cohortA10.804
6MBCProject_0375_T1_B_RNA
breast-umap@18
—D0.798
7SRR12202481
bladder-landscape@3
——0.791
846a6f49d-2ab8-41fb-ba8c-951a160e5d08
colon-landscapes@1
——0.789
9ULC0085T_S41
lung-landscapes@6
—cohortA10.789
10AUR-AFR5-TTP1-A-1-1-R-A743-41
breast-umap@18
—D0.787

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_GAMMA_RESPONSE0.421Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.406Inavolisib— uncovered
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.259Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.254Idelalisib— uncovered
APICAL_SURFACE0.212Temsirolimus— uncovered
WNT_BETA_CATENIN_SIGNALING0.203Inavolisib— uncovered
KRAS_SIGNALING_UP0.157Inavolisib— uncovered
ANGIOGENESIS0.154Remibrutinib— uncovered
COMPLEMENT0.102Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.101Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.099Inavolisib— uncovered
SPERMATOGENESIS0.078Inavolisib— uncovered
MYOGENESIS0.076Inavolisib— uncovered
COAGULATION0.060Binimetinib— uncovered
KRAS_SIGNALING_DN0.059Remibrutinib— uncovered
APICAL_JUNCTION0.040Inavolisib— uncovered
MYC_TARGETS_V20.017Idelalisib— uncovered
E2F_TARGETS0.013Inavolisib— uncovered
IL2_STAT5_SIGNALING0.013Idelalisib— uncovered